CD19 and neoplasm: Preclinical models revealed that T cells transfected with RNA (e.g., encoding mesothelin-, CD19-, or chondroitin sulfate proteoglycan 4 (CSPG4)-specific CARs) showed anti-tumor effects in vitro and in vivo [22,23,24].